LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

26.57 -2.06

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.14

Max

27.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
EPS	-1.01
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-3.2M -66M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+101.69% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	295M 1.8B
Vorige openingsprijs	28.63
Vorige sluitingsprijs	26.57

Nieuwssentiment

By Acuity

50%

166 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 dec 2025, 23:54 UTC

Belangrijke Marktbewegers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec 2025, 19:08 UTC

Acquisities, Fusies, Overnames

Correction to Alphabet to Buy Intersect Article

22 dec 2025, 17:21 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec 2025, 23:42 UTC

Marktinformatie

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec 2025, 22:30 UTC

Winsten

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 21:37 UTC

Acquisities, Fusies, Overnames

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec 2025, 20:52 UTC

Acquisities, Fusies, Overnames

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec 2025, 20:09 UTC

Marktinformatie

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec 2025, 19:56 UTC

Marktinformatie

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec 2025, 19:49 UTC

Acquisities, Fusies, Overnames

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec 2025, 19:23 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec 2025, 19:23 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Precious Metals Climb to New Heights -- Market Talk

22 dec 2025, 18:45 UTC

Marktinformatie

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec 2025, 18:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec 2025, 18:23 UTC

Acquisities, Fusies, Overnames

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 dec 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

101.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55 USD 101.69%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

166 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.